Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

309
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
309
Positron Emission Tomography01:29

Positron Emission Tomography

6.5K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lineage infidelity in FH-deficient RCC with secondary somatic alterations: a case report and implications for diagnosis and treatment.

Therapeutic advances in medical oncology·2026
Same author

Cancer-associated fibroblast activation protein in Appalachian women with uterine cervix cancer.

Frontiers in oncology·2026
Same author

Tarlatamab in Previously Treated Small Cell Lung Cancer: A Real-World Experience in a Predominantly Hispanic Population with CNS Metastases.

Cancers·2026
Same author

Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study.

European urology oncology·2026
Same author

Deep Eutectic Solvent-Mediated Nucleation Engineering of Bi<sub>2</sub>WO<sub>6</sub> Photocatalysts for Enhanced Visible Light Degradation of Organic Pollutants.

Langmuir : the ACS journal of surfaces and colloids·2026
Same author

Insulin Pathway Changes in Localized Prostate Cancer: A Multi-Institutional Analysis.

Cancers·2026
Same journal

Explainable incremental-value analysis of apparent diffusion coefficient and arterial spin labeling radiomics for ATRX status prediction in glioblastoma.

Frontiers in oncology·2026
Same journal

Study-level factors associated with hematoma after ultrasound-guided vacuum-assisted breast lesion excision: a systematic review and meta-analysis using a T-P-B framework.

Frontiers in oncology·2026
Same journal

Feasibility and strategy analysis of radiotherapy consolidation following immunotherapy for stage IV esophageal squamous cell carcinoma.

Frontiers in oncology·2026
Same journal

Anastomosing hemangioma of the kidney: a case report.

Frontiers in oncology·2026
Same journal

Machine learning-based prediction of prolonged air leak after uniportal video-assisted thoracic surgery segmentectomy.

Frontiers in oncology·2026
Same journal

Past present and future of radiosensitization in cervical cancer.

Frontiers in oncology·2026
See all related articles

Related Experiment Video

Updated: Nov 12, 2025

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

657

Radiopharmaceutical Validation for Clinical Use.

Charles A Kunos1, Rodney Howells1, Aman Chauhan2

  • 1Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, United States.

Frontiers in Oncology
|March 22, 2021
PubMed
Summary
This summary is machine-generated.

Developing anticancer radiopharmaceuticals requires standardized validation guidelines. This article outlines four evidence levels to ensure agent specificity, selectivity, and tumor delivery for effective cancer treatment.

Keywords:
nuclear medicinepreclinicalradiation oncologyradiopharmaceuticalvalidation

More Related Videos

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases
11:03

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Published on: May 29, 2017

10.2K
Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

1.7K

Related Experiment Videos

Last Updated: Nov 12, 2025

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

657
Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases
11:03

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Published on: May 29, 2017

10.2K
Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

1.7K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Drug Development

Background:

  • Radiopharmaceuticals are gaining traction as anticancer agents.
  • Current lack of standardized validation guidelines hinders early-phase clinical trials for radiopharmaceuticals.
  • Ensuring specificity, selectivity, and tumor delivery is crucial for therapeutic radiopharmaceuticals.

Purpose of the Study:

  • To propose a framework for validating oncology therapeutic radiopharmaceuticals.
  • To discuss evidence levels for justifying radiopharmaceutical use in early-phase trials.
  • To highlight common pitfalls and operational steps in radiopharmaceutical drug development.

Main Methods:

  • Discusses four levels of evidence: target antigen immunohistochemistry, in vitro and in vivo preclinical experiments, animal biodistribution and dosimetry studies, and first-in-human microdose biodistribution studies.
  • Reviews common practices and operationalizing steps for early-phase radiopharmaceutical trials.

Main Results:

  • Identifies key evidence levels essential for validating radiopharmaceuticals.
  • Outlines practical considerations for implementing radiopharmaceutical trials.

Conclusions:

  • Standardized validation is critical for the successful development of anticancer radiopharmaceuticals.
  • The proposed evidence-based approach can guide radiopharmaceutical drug development.
  • Expect an increase in radiopharmaceutical trials within the National Cancer Institute Cancer Therapy Evaluation Program (CTEP) portfolio.